Correction to: Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome (Pharmaceutical Biology, (2016), 54, 6, (975-983), 10.3109/13880209.2015.1091482);Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome

Pharmaceutical Biology

Volumn 54, Issue 6, 2016, Pages 975-983

  Shah, Krushangi N ^a   Patel, Snehal S ^b  

^a Lambda Therapeut Research Pvt Ltd   (India)

^b NIRMA UNIVERSITY   (India)

Author keywords

CYP17A1; cystic ovary; folliculogenesis; insulin resistance; quercetin; steroidogenesis

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; GSK 105915; INSULIN; LUTEINIZING HORMONE; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; QUERCETIN; TESTOSTERONE; UNCLASSIFIED DRUG; WORTMANNIN; CYP17A1 PROTEIN, RAT; PROTEIN BINDING; STEROID 17ALPHA MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYP17A1 GENE; DRUG BINDING; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; ESTRUS CYCLE; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HYPERANDROGENISM; HYPERINSULINEMIA; MOLECULAR DOCKING; NONHUMAN; ORGAN WEIGHT; OVARY POLYCYSTIC DISEASE; OVARY WEIGHT; RAT; REMISSION; UTERUS WEIGHT; WEIGHT GAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; ORGAN SIZE; OVARY; PATHOLOGY; POLYCYSTIC OVARY SYNDROME; SPRAGUE DAWLEY RAT; UTERUS;

ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; ESTROUS CYCLE; FEMALE; GENE EXPRESSION; MOLECULAR DOCKING SIMULATION; ORGAN SIZE; OVARY; PHOSPHATIDYLINOSITOL 3-KINASE; POLYCYSTIC OVARY SYNDROME; PROTEIN BINDING; QUERCETIN; RATS, SPRAGUE-DAWLEY; STEROID 17-ALPHA-HYDROXYLASE; UTERUS;

EID: 84945236985     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880209.2023.2233815     Document Type: Erratum

References (30)

1. Aguirre L, Arias N, Macarulla MT, et al. 2011. Beneficial effects of quercetin on obesity and diabetes. Open Nutraceuticals J. 4:189-198.
2. Bahceci M, Aydemir M, Tuzcu A. 2007. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril. 87:1363-1368.
3. Baillargeon JP, Iuorno MJ, Nestler JE. 2003. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 46:325-340.
4. Barber TM, Bennett AJ, Groves CJ, et al. 2008. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia 51:1153-1158.
5. Bogovich K, Richards JS. 1982. Androgen biosynthesis in developing ovarian follicles: evidence that luteinizing hormone regulates thecal 17 alpha-hydroxylase and C17-20-lyase activities. Endocrinology 111:1201-1208.
6. Carvalho CR, Carvalheira JB, Lima MH, et al. 2003. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 144:638-647.
7. Doi SA, Al-Zaid M, Towers PA, et al. 2005. Irregular cycles and steroid hormones in polycystic ovary syndrome. Hum Reprod. 20:2402-2408.
8. Duez H, Lamarche B, Valéro R, et al. 2008. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 117:2369-2376.
9. Franks S, Mason H, Willis D. 2000. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol. 25:49-52.
10. Fukuda S, Orisaka M, Tajima K, et al. 2009. Luteinizing hormone-induced Akt phosphorylation and androgen production are modulated by MAP kinase in bovine theca cells. J Ovarian Res. 2:17-24.
11. Hollman PC, De Vries JH, van Leeuwen SD, et al. 1995. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr. 62:1276-1282.
12. Honnma H, Endo T, Henmi H, et al. 2006. Altered expression of Fas/Fas ligand/caspase 8 and membrane type 1-matrix metalloproteinase in atretic follicles within dehydroepiandrosterone-induced polycystic ovaries in rats. Apoptosis 11:1525-1533.
13. Juywiak S, Wójcicki J, Mokrzycki K, et al. 2005. Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol Rep. 57:604-609.
14. Kafali H, Iriadam M, Ozardali I, et al. 2004. Letrozole-induced polycystic ovaries in the rat: A new model for cystic ovarian disease. Arch Med Res. 35:103-108.
15. Krishna PS, Vani K, Prasad MR, et al. 2013. In silico molecular docking analysis of prodigiosin and cycloprodigiosin as COX-2 inhibitors. Springerplus 2:172-179.
16. Lansdown A, Rees DA. 2012. The sympathetic nervous system in polycystic ovary syndrome: A novel therapeutic target ? Clin Endocrinol (Oxf). 77:791-801.
17. Li M, Youngren JF, Dunaif A, et al. 2002. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab. 87:4088-4093.
18. Linares R, Hernandez D, Moran C, et al. 2013. Unilateral or bilateral vagotomy induces ovulation in both ovaries of rats with polycystic ovarian syndrome. Reprod Biol Endocrinol. 11:68-77.
19. Mendonca HC, Montenegro RM, Foss MC, et al. 2004. Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome. Braz J Med Biol Res. 37:729-736.
20. Moghetti P, Castello R, Negri C, et al. 2000. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 85:139-146.
21. Munir I, Yen H, Geller DH, et al. 2004. Insulin augmentation of 17a-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology 145:175-183.
22. Musso C, Shawker T, Cochran E, et al. 2005. Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth. Clin Endocrinol (Oxf). 63:73-78.
23. Ota H, Fukushima M, Maki M. 1983. Endocrinological and histological aspects of the process of polycystic ovary formation in the rat treated with testosterone propionate. Tohoku J Exp Med. 140:121-131.
24. Shah KN, Patel SS. 2014. Phosphatidylinositide 3-kinase: A newer molecular target in metabolic and hormonal pathway of polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 122:261-267.
25. Vandermolen DT, Ratts VS, Evans WS, et al. 2001. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril. 75:310-315.
26. Walker EH, Pacold ME, Perisic O, et al. 2000. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 6:909-919.
27. Wang F, Yu B, Yang W, et al. 2012. Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats. J Ovarian Res. 5:15-21.
28. Wickenheisser JK, Nelson-Degrave VL, McAllister JM. 2005. Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab. 90:1720-1727.
29. Yaba A, Demir N. 2012. The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS). J Ovarian Res. 5:38-50.
30. Zhai HL, Wu H, Xu H, et al. 2012. Trace glucose and lipid metabolism in high androgen and high-fat diet induced polycystic ovary syndrome rats. Reprod Biol Endocrinol. 10:5-13.